Login to Your Account



No Abraxane pain wane; will combinations unlock big Celgene I-O dough?

By Randy Osborne
Staff Writer

Thursday, November 5, 2015

The cancer drug Abraxane chalked up another weak showing in third quarter earnings for Celgene Corp., and Jacqualyn Fouse, global head of hematology and oncology, blamed the "big impact from the first wave" of immuno-oncology therapies.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription